TOP TEN perturbations for Q96KN8 (Homo sapiens)

Organism: Homo sapiens
Gene: Q96KN8
Selected probe(set): 231050_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of Q96KN8 (231050_at) across 5339 perturbations tested by GENEVESTIGATOR:

breast cancer study 8 (primary) / normal breast tissue

Relative Expression (log2-ratio):-3.1620731
Number of Samples:13 / 4
Experimental breast cancer study 8 (primary)
Human primary infiltrating ductal carcinoma sample of a female patient with breast cancer.
Control normal breast tissue
Normal human breast samples of healthy female individuals.

breast cancer study 8 (metastatic) / normal breast tissue

Relative Expression (log2-ratio):-3.0353527
Number of Samples:2 / 4
Experimental breast cancer study 8 (metastatic)
Human metastatic infiltrating ductal carcinoma sample of the breast derived from lymph nodes of a female patient with breast cancer.
Control normal breast tissue
Normal human breast samples of healthy female individuals.

stem cell differentiation study 47 (BMP-2; IBMX; 7d) / stem cell differentiation study 47 (BMP-2; TGFb; 7d)

Relative Expression (log2-ratio):2.9679375
Number of Samples:3 / 3
Experimental stem cell differentiation study 47 (BMP-2; IBMX; 7d)
Bone marrow-derived mesenchymal stem cell line (MSC) differentiated for 7 days in the presence of bone morphogenetic protein 2 (BMP-2, 50ng/ml) and 3-isobutyl-1-methylxanthine (IBMX, 250 ?M). Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 ?C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (PM, high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 ?g/ml streptomycin). Subsequently PMCs were differentiated for 7 days in differentiation medium (consisting of PM with 10EXP(-6)M dexamethasone, 10 ?g/ml insulin, 10EXP(-7) M rosiglitazone, 50 ng/ml BMP-2, 250 ?M IBMX), and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458).
Control stem cell differentiation study 47 (BMP-2; TGFb; 7d)
Bone marrow-derived mesenchymal stem cell line (MSC) differentiated for 7 days in the presence of bone morphogenetic protein 2 (BMP-2, 50ng/ml) and transforming growth factor beta (TGFb, 5 ng/ml). Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 ?C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (PM, high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 ?g/ml streptomycin). Subsequently PMCs were differentiated for 7 days in differentiation medium (consisting of PM with 10EXP(-6)M dexamethasone, 10 ?g/ml insulin, 10EXP(-7) M rosiglitazone, 50 ng/ml BMP-2, 5 ng/ml TGFb), and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458).

stem cell differentiation study 47 (BMP-2; IBMX; 7d) / stem cell differentiation study 47 (BMP-2; IBMX; 1d)

Relative Expression (log2-ratio):2.9642982
Number of Samples:3 / 3
Experimental stem cell differentiation study 47 (BMP-2; IBMX; 7d)
Bone marrow-derived mesenchymal stem cell line (MSC) differentiated for 7 days in the presence of bone morphogenetic protein 2 (BMP-2, 50ng/ml) and 3-isobutyl-1-methylxanthine (IBMX, 250 ?M). Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 ?C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (PM, high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 ?g/ml streptomycin). Subsequently PMCs were differentiated for 7 days in differentiation medium (consisting of PM with 10EXP(-6)M dexamethasone, 10 ?g/ml insulin, 10EXP(-7) M rosiglitazone, 50 ng/ml BMP-2, 250 ?M IBMX), and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458).
Control stem cell differentiation study 47 (BMP-2; IBMX; 1d)
Bone marrow-derived mesenchymal stem cell line (MSC) differentiated for 24 hours in the presence of bone morphogenetic protein 2 (BMP-2, 50ng/ml) and 3-isobutyl-1-methylxanthine (IBMX, 250 ?M). Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 ?C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (PM, high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 ?g/ml streptomycin). Subsequently PMCs were differentiated for 1 day in differentiation medium (consisting of PM with 10EXP(-6)M dexamethasone, 10 ?g/ml insulin, 10EXP(-7) M rosiglitazone, 50 ng/ml BMP-2, 250 ?M IBMX), and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458).

stem cell differentiation study 47 (BMP-2; IBMX; 7d) / stem cell differentiation study 47 (0d)

Relative Expression (log2-ratio):2.8953552
Number of Samples:3 / 6
Experimental stem cell differentiation study 47 (BMP-2; IBMX; 7d)
Bone marrow-derived mesenchymal stem cell line (MSC) differentiated for 7 days in the presence of bone morphogenetic protein 2 (BMP-2, 50ng/ml) and 3-isobutyl-1-methylxanthine (IBMX, 250 ?M). Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 ?C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (PM, high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 ?g/ml streptomycin). Subsequently PMCs were differentiated for 7 days in differentiation medium (consisting of PM with 10EXP(-6)M dexamethasone, 10 ?g/ml insulin, 10EXP(-7) M rosiglitazone, 50 ng/ml BMP-2, 250 ?M IBMX), and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458).
Control stem cell differentiation study 47 (0d)
Undifferentiated bone marrow-derived mesenchymal stem cell line (MSC) without any treatment. Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 ?C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 ?g/ml streptomycin) and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458).

stem cell differentiation study 47 (BMP-2; IBMX; 7d) / stem cell differentiation study 47 (BMP-2; IBMX; 2d)

Relative Expression (log2-ratio):2.8676653
Number of Samples:3 / 3
Experimental stem cell differentiation study 47 (BMP-2; IBMX; 7d)
Bone marrow-derived mesenchymal stem cell line (MSC) differentiated for 7 days in the presence of bone morphogenetic protein 2 (BMP-2, 50ng/ml) and 3-isobutyl-1-methylxanthine (IBMX, 250 ?M). Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 ?C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (PM, high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 ?g/ml streptomycin). Subsequently PMCs were differentiated for 7 days in differentiation medium (consisting of PM with 10EXP(-6)M dexamethasone, 10 ?g/ml insulin, 10EXP(-7) M rosiglitazone, 50 ng/ml BMP-2, 250 ?M IBMX), and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458).
Control stem cell differentiation study 47 (BMP-2; IBMX; 2d)
Bone marrow-derived mesenchymal stem cell line (MSC) differentiated for 2 days in the presence of bone morphogenetic protein 2 (BMP-2, 50ng/ml) and 3-isobutyl-1-methylxanthine (IBMX, 250 ?M). Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 ?C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (PM, high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 ?g/ml streptomycin). Subsequently PMCs were differentiated for 2 days in differentiation medium (consisting of PM with 10EXP(-6)M dexamethasone, 10 ?g/ml insulin, 10EXP(-7) M rosiglitazone, 50 ng/ml BMP-2, 250 ?M IBMX), and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458).

stem cell differentiation study 47 (BMP-2; IBMX; 7d) / stem cell differentiation study 47 (BMP-2; IBMX; 3d)

Relative Expression (log2-ratio):2.841917
Number of Samples:3 / 3
Experimental stem cell differentiation study 47 (BMP-2; IBMX; 7d)
Bone marrow-derived mesenchymal stem cell line (MSC) differentiated for 7 days in the presence of bone morphogenetic protein 2 (BMP-2, 50ng/ml) and 3-isobutyl-1-methylxanthine (IBMX, 250 ?M). Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 ?C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (PM, high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 ?g/ml streptomycin). Subsequently PMCs were differentiated for 7 days in differentiation medium (consisting of PM with 10EXP(-6)M dexamethasone, 10 ?g/ml insulin, 10EXP(-7) M rosiglitazone, 50 ng/ml BMP-2, 250 ?M IBMX), and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458).
Control stem cell differentiation study 47 (BMP-2; IBMX; 3d)
Bone marrow-derived mesenchymal stem cell line (MSC) differentiated for 3 days in the presence of bone morphogenetic protein 2 (BMP-2, 50ng/ml) and 3-isobutyl-1-methylxanthine (IBMX, 250 ?M). Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 ?C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (PM, high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 ?g/ml streptomycin). Subsequently PMCs were differentiated for 3 days in differentiation medium (consisting of PM with 10EXP(-6)M dexamethasone, 10 ?g/ml insulin, 10EXP(-7) M rosiglitazone, 50 ng/ml BMP-2, 250 ?M IBMX), and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458).

breast cancer study 15 (inv. dc) / normal breast tissue

Relative Expression (log2-ratio):-2.71764
Number of Samples:5 / 5
Experimental breast cancer study 15 (inv. dc)
Primary invasive ductal carcinoma tissue sample derived from the breasts of female patients after surgery.
Control normal breast tissue
Tissue samples of the breast from healthy female individuals after breast reduction surgery.

breast cancer study 16 (inv. dc) / adjacent breast tissue

Relative Expression (log2-ratio):-2.659419
Number of Samples:22 / 27
Experimental breast cancer study 16 (inv. dc)
Primary invasive ductal carcinoma tissue sample derived from the breasts of female patients after surgery.
Control adjacent breast tissue
Histologically normal breast tissue samples obtained from a clinically unaffected site from patients with primary invasive breast cancer.

male infertility study 1 (juvenile; Ad+) / normal testicular lobules tissue (mJS10)

Relative Expression (log2-ratio):-2.6168299
Number of Samples:5 / 8
Experimental male infertility study 1 (juvenile; Ad+)
Human testicular lobules biopsy samples isolated from prepubescent patients with undescended testes. Testes of these children contained typical level of A-dark (Ad+) spermatogonial cells.
Control normal testicular lobules tissue (mJS10)
Biopsies of human testicular lobules isolated from fertile vasectomized adult men with normal spermatogenesis. Histological analysis classified samples as mJS10 (modified Johnsen score 10).